Therapeutics News and Research

RSS

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Proteros Biostructures GmbH announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K.

25 May 2011

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

A rare genetic disease called dyskeratosis congenita, caused by the rapid shortening of telomeres, can be mimicked through the study of undifferentiated induced pluripotent stem cells, according to new findings from the Stanford University School of Medicine.

24 May 2011

Accelerator announces Series A financing of Oncofactor

Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator.

24 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

Substantial portion of patients with headaches improve without treatment

Headache is a very common complaint, with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions.

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

NIH allocated $400 million funding for pain research in 2010

An unprecedented level of federal funding for pain research, some $400 million, was allocated in 2010 by the National Institutes of Health (NIH) through provisions of the American Recovery and Investment Act and the Affordable Care Act to help accelerate advances in pain research, prevention and treatment.

21 May 2011

Edurant receives FDA approval for treatment of HIV-1 infection

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

21 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Researchers at the University of California, San Diego School of Medicine have uncovered new details of an unusual biological mechanism in the brains of diverse species that not only helps regulate how their brains develop, but also how they function later in life. The discovery could lead to new biomarkers for specific neurological diseases in humans and, possibly, the development of drugs to cure them.

21 May 2011

USPTO awards Serina patent for polymer drug delivery technology

Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Therapeutics News and Research

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

Accelerator announces Series A financing of Oncofactor

Exosome Diagnostics announces expansion of scientific advisory board

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Substantial portion of patients with headaches improve without treatment

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Novel compound could become an effective alternative to common narcotic analgesics

NIH allocated $400 million funding for pain research in 2010

Edurant receives FDA approval for treatment of HIV-1 infection

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Researchers uncover new details of unusual biological mechanism in brains of diverse species

USPTO awards Serina patent for polymer drug delivery technology

EMA CHMP recommends conditional marketing authorization of FAMPYRA

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News